Sphingolipids: players in the pathology of metabolic disease.
about
OSBP-related proteins (ORPs) in human adipose depots and cultured adipocytes: evidence for impacts on the adipocyte phenotypeFrom Molecules to the Clinic: Linking Schizophrenia and Metabolic Syndrome through Sphingolipids MetabolismTorpor induction in mammals: recent discoveries fueling new ideasInsulin resistance is associated with higher intramyocellular triglycerides in type I but not type II myocytes concomitant with higher ceramide content.Traveling from the hypothalamus to the adipose tissue: The thermogenic pathwaySphingosine 1-phosphate lyase deficiency disrupts lipid homeostasis in liverHigh fat diet induced hepatic steatosis and insulin resistance: Role of dysregulated ceramide metabolism.Discovery and evaluation of inhibitors of human ceramidase.Imaging of phospholipids in formalin fixed rat brain sections by matrix assisted laser desorption/ionization mass spectrometry.Blood sphingolipidomics in healthy humans: impact of sample collection methodology.Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.Hepatic accumulation of intestinal cholesterol is decreased and fecal cholesterol excretion is increased in mice fed a high-fat diet supplemented with milk phospholipids.Inflammatory induction of human resistin causes insulin resistance in endotoxemic mice.Altered sphingoid base profiles in type 1 compared to type 2 diabetes.Desorption electrospray ionization mass spectrometry for lipid characterization and biological tissue imaging.Classifying human brain tumors by lipid imaging with mass spectrometryInsulin resistance, ceramide accumulation, and endoplasmic reticulum stress in human chronic alcohol-related liver disease.Soy Protein Isolate Protects Against Ethanol-Mediated Tumor Progression in Diethylnitrosamine-Treated Male MiceDysfunctional pro-ceramide, ER stress, and insulin/IGF signaling networks with progression of Alzheimer's diseaseMyristate-derived d16:0 sphingolipids constitute a cardiac sphingolipid pool with distinct synthetic routes and functional properties.Skeletal muscle triacylglycerol hydrolysis does not influence metabolic complications of obesity.Sphingosine kinase 1 is regulated by peroxisome proliferator-activated receptor α in response to free fatty acids and is essential for skeletal muscle interleukin-6 production and signaling in diet-induced obesity.Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance by increasing de novo synthesis of long-chain ceramides.Central ceramide-induced hypothalamic lipotoxicity and ER stress regulate energy balanceInsulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis.Risk of death in heart disease is associated with elevated urinary globotriaosylceramide.The role of sphingolipids in drug metabolism and transport.Stress and obesity as risk factors in cardiovascular diseases: a neuroimmune perspective.Quantitative metabolic profiling of lipid mediators.Targeting sphingolipid metabolism in the treatment of obesity/type 2 diabetes.Therapeutic Strategies and Pharmacological Tools Influencing S1P Signaling and Metabolism.Comparative Analysis of Biological Sphingolipids with Glycerophospholipids and Diacylglycerol by LC-MS/MSMoving beyond "good fat, bad fat": the complex roles of dietary lipids in cellular function and health: session abstracts.A rapid and quantitative LC-MS/MS method to profile sphingolipids.Time-dependent changes in lipid metabolism in mice with methionine choline deficiency-induced fatty liver diseaseProtective effects of fish oil on pre-diabetes: a lipidomic analysis of liver ceramides in rats.Translational Aspects of Sphingolipid Metabolism in Renal Disorders.FTY720P inhibits hepatic Na(+)-K(+) ATPase via S1PR2 and PGE2.The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl-2 inhibitor (ABT-199) displays synergistic anti-myeloma effects in myeloma cells without a t(11;14) translocation.Phytochemistry, Antioxidant, and Hepatoprotective Potential of Acanthospermum hispidum DC Extracts against Diethylnitrosamine-Induced Hepatotoxicity in Rats.
P2860
Q24300076-36B99FCE-39D4-45EE-ADC3-5A5E916AAFD3Q28067617-679BD5A3-6252-4717-A6F3-6DEEEA1AC36BQ28749655-4FF8431D-1E1A-460B-9089-9CE9D8E5F199Q33556682-EB871723-60DF-48C2-B519-511DDCA3860AQ33607493-5B27EE3E-97D5-4FEC-98E2-0D88E824BBA2Q33796272-8BE72979-20AE-445F-A7DD-555B39F363E2Q33896110-2AB65978-149B-409D-A205-7FF3373C9516Q34008335-55F4A564-D1EC-4A71-8CDD-15BE824D2AEBQ34032993-93DEB36F-63F7-4501-B17C-BC9215D03152Q34116310-BDB7BAE9-9044-4DFC-A4A2-8946E399D27DQ34209320-8B4491EC-A0E2-4EE4-B5A8-9F6BE945DA59Q34506779-34E8802D-419E-4817-962C-84351640F893Q34615398-AAAE7508-9ED1-46E6-8E4B-9D4DD9489EB7Q34740094-6EE3F927-74FC-406E-B5CD-190965FAC608Q35491243-88DF47DB-C235-4681-82BD-3539C52211FBQ35729801-CD9C36FD-F342-4597-9154-7098AEF9D2DAQ35944938-40F2FC29-7449-4B99-9D9A-2292118B950DQ35967096-13B390C3-77CA-4A9F-A454-4FDFA6DDC85AQ36036789-76E5F694-4703-4B6B-ADCB-E8D3FC9AFADEQ36832610-5BA25BD0-3754-4527-B8D4-41C515135948Q37193401-8661F541-2E80-4414-9B36-9B083E549B10Q37311833-B4A09FB8-C8EC-47B9-B7F1-225A17E9BA5CQ37339555-A27FF4E1-76EA-405F-B4D4-2E4BA63B19D3Q37505073-66809479-DB4B-46DC-ABE8-35FE01F8D2BDQ37602608-3435761B-818A-41A4-AC4E-93CF5B45B0CDQ37648595-9EFEF4C5-31AD-4BAC-8B8D-D77D3BF0D9B3Q38071694-097E71AD-E999-4000-B595-912139FD339AQ38074862-F1C83024-A0C9-4E6A-9D0B-8A3E34CA3987Q38119472-F0E8B4BD-42D8-4D9A-8553-D5441634DF64Q38392764-854FE735-26C8-4FE3-9539-573AC6AF9E57Q38915115-773DD5E7-FBE8-4DE3-8046-8E9725808AC6Q39532828-64621F49-D92D-4A7C-BC1D-9D05A626484AQ40548978-9E6BAD28-3F6E-45B7-99AC-D29AE781BA3BQ40948476-62428F7E-641A-4C45-9917-514C47CBC3BDQ41864276-FEE4A2DB-B89B-4517-AE95-114AF2C5D4E1Q48311591-92221C16-ACF4-442F-9C61-47B4A4A1A0EAQ49399657-9AA61992-046C-441B-A032-6B81BE0D9A28Q51585253-748FA266-6A71-496E-8352-F4ECDDB933A6Q53682262-6EB8199F-6771-4800-906A-FE4CD946F756Q53685086-61CDC031-95CE-45A6-BFF8-6BA5B935D35B
P2860
Sphingolipids: players in the pathology of metabolic disease.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Sphingolipids: players in the pathology of metabolic disease.
@en
Sphingolipids: players in the pathology of metabolic disease.
@nl
type
label
Sphingolipids: players in the pathology of metabolic disease.
@en
Sphingolipids: players in the pathology of metabolic disease.
@nl
prefLabel
Sphingolipids: players in the pathology of metabolic disease.
@en
Sphingolipids: players in the pathology of metabolic disease.
@nl
P1476
Sphingolipids: players in the pathology of metabolic disease.
@en
P2093
L Ashley Cowart
P356
10.1016/J.TEM.2008.09.004
P577
2008-11-13T00:00:00Z